Producer of medical devices PolyNovo (ASX:PNV) has announced further sales of its NovoSorb product in the US, after receiving an order from another US hospital and a reorder from an existing contract.
NovoSorb is used by surgeons for reconstructive surgery to help regenerate the skin after burn damage, trauma and wounds.
The company sees these sales and reorder as a sign for further repeat orders and market penetration.
According to PolyNovo, the uptake of its product in hospitals is demonstrating successful clinical results.
The product has FDA approval for surgical wound application in the US, Australia, South Africa and New Zealand.
Shares in PolyNovo (ASX:PNV) last traded 1.79 per cent higher to 29 cents a share.